Multiple states across the country are suing major drugmakers over misleading marketing practices, and the cases span everything from blood thinners and pain relievers to blockbuster weight-loss drugs. Texas alone has filed at least three major lawsuits against pharmaceutical giants since late 2025, alleging that companies like Bristol-Myers Squibb, Johnson & Johnson, and Eli Lilly deliberately misled patients and physicians about the safety, effectiveness, or marketing of widely prescribed medications. For families affected by dementia and other neurological conditions, these cases matter — some involve drugs linked to neurodevelopmental concerns, while others expose systemic patterns of deception that erode trust in the medications millions of people depend on daily.
The legal actions are not limited to individual states. A 50-state settlement forced Boehringer Ingelheim to pay $13.5 million over deceptive marketing of drugs including Aggrenox, a medication commonly prescribed to prevent strokes — a significant concern for those managing vascular dementia risk. Meanwhile, the FDA itself stepped in to flag Novo Nordisk’s television ads for the new Wegovy pill as misleading in early 2026. This article examines the major cases now making their way through courts and regulatory channels, what the allegations mean for patients and caregivers, and how these legal battles could reshape pharmaceutical marketing standards going forward.
Table of Contents
- Why Are States Suing Drugmakers Over Misleading Medication Marketing?
- The Tylenol-Autism Lawsuit and What It Means for Neurodevelopmental Health
- How Kickback Schemes Distort Prescribing Decisions
- What the FDA’s Wegovy Ad Warning Tells Us About Drug Marketing Tactics
- Multistate Settlements and the Scope of Generic Drug Price-Fixing
- How These Cases Affect Patients Managing Dementia and Brain Health
- What Comes Next in the Fight Against Misleading Drug Marketing
- Conclusion
- Frequently Asked Questions
Why Are States Suing Drugmakers Over Misleading Medication Marketing?
The short answer is money and public health. State attorneys general have increasingly turned to consumer protection and healthcare fraud statutes to hold pharmaceutical companies accountable when their marketing crosses the line from aggressive promotion into outright deception. Texas Attorney General Ken Paxton has been particularly active, filing suit against Bristol-Myers Squibb and Sanofi in November 2025 over their marketing of Plavix, a widely prescribed blood thinner. The allegation is striking: Paxton claims both companies knew as far back as 1998 that Plavix had diminished or no effectiveness in Black, East Asian, and Pacific Islander patients due to genetic variations in how those populations metabolize the drug. The FDA did not add a black box warning about this reduced effectiveness until 2010 — more than a decade after the companies allegedly had the data in hand. What makes these lawsuits different from typical pharmaceutical litigation is the legal basis. Rather than relying solely on product liability claims from individual patients, states are invoking broad consumer protection laws like the Texas Deceptive Trade Practices-Consumer Protection Act and state healthcare fraud prevention statutes.
This approach allows attorneys general to seek penalties on behalf of entire populations, not just individual plaintiffs. The Plavix case, for example, argues that the companies “made billions” while an entire segment of the population received a medication that was essentially a placebo for them. For older adults managing stroke and clot risk — conditions intimately connected to vascular dementia — the implications of prescribing an ineffective blood thinner are severe. The pattern extends well beyond Texas. A coalition of all 50 states and the District of Columbia reached a $13.5 million settlement with Boehringer Ingelheim over deceptive marketing of four prescription drugs, including Micardis and Aggrenox. And 48 states joined forces to secure $17.85 million from Lannett and Bausch Health over generic drug price-fixing conspiracies. These multistate actions signal that misleading pharmaceutical marketing is no longer treated as a cost of doing business — it is treated as fraud.
The Tylenol-Autism Lawsuit and What It Means for Neurodevelopmental Health
In October 2025, Texas became the first state government to sue Johnson & Johnson and its spinoff Kenvue over claims that Tylenol was deceptively marketed to pregnant mothers. The core allegation: the companies knew that prenatal exposure to acetaminophen may lead to a significantly increased risk of autism and other neurodevelopmental disorders in children, yet continued marketing the drug as safe during pregnancy without adequate warnings. The lawsuit was filed under the Texas Deceptive Trade Practices Act and the Uniform Fraudulent Transfer Act, and it arrived just one month after President Trump and HHS Secretary Robert F. Kennedy Jr. announced updated federal guidance discouraging pregnant women from taking acetaminophen. However, this case comes with a significant scientific caveat that anyone following it should understand.
The link between acetaminophen and autism remains scientifically contested. A 2024 study published in JAMA found no causal link between prenatal acetaminophen exposure and autism spectrum disorder, and major health authorities have not confirmed a causal relationship. Kenvue has stated it will “vigorously defend itself” and stands “firmly with the global medical community that acknowledges the safety of acetaminophen.” This means the Texas lawsuit is, in part, a legal test of whether state consumer protection law can be used to force warning labels based on emerging but unconfirmed science — a precedent that could reshape how all medications are marketed to vulnerable populations. For the dementia and brain health community, this case raises important questions about how neurodevelopmental risks are communicated to the public. Whether or not the acetaminophen-autism link is ultimately confirmed, the lawsuit highlights a broader tension in pharmaceutical marketing: companies have financial incentives to minimize safety concerns, while patients and caregivers need complete, transparent information to make informed decisions. If the Texas case succeeds, it could open the door to similar lawsuits involving medications where neurological side effects are suspected but not yet conclusively proven — a category that includes several drugs prescribed to older adults.
How Kickback Schemes Distort Prescribing Decisions
Not all misleading marketing involves television ads or product labels. In some cases, the deception happens behind the scenes, through financial arrangements that corrupt the prescribing process itself. Texas filed suit against Eli Lilly, alleging the company bribed medical providers to prescribe its most profitable drugs — including the blockbuster GLP-1 medications Mounjaro and Zepbound — through a so-called “Free Nurse Program.” According to the lawsuit, Eli Lilly provided free patient-care services to medical practices as a quid pro quo for prescribing a long list of its drugs, including Mounjaro, Zepbound, Humalog, Humulin, Forteo, and over a dozen others. The state alleges this arrangement resulted in millions of dollars in tainted Medicaid claims, meaning taxpayers were footing the bill for prescriptions influenced by kickbacks rather than clinical judgment.
Eli Lilly denied the charges and pointed out that “multiple courts and federal governments have rejected claims by this same corporate relator against Lilly as meritless.” Still, the case underscores a reality that patients and caregivers should be aware of: the drug your doctor prescribes may not always reflect a purely clinical decision. When pharmaceutical companies embed their own staff in medical offices, the line between patient support and sales influence gets dangerously thin. For older adults managing diabetes alongside cognitive decline — a common pairing, since diabetes is a well-established risk factor for dementia — the Eli Lilly case is particularly relevant. If prescribing decisions for diabetes medications are being shaped by financial incentives rather than individual patient needs, the downstream effects on brain health could be substantial. Proper diabetes management can slow cognitive decline, but only if the prescribed medication is the right fit for the patient, not just the most profitable option for the manufacturer.
What the FDA’s Wegovy Ad Warning Tells Us About Drug Marketing Tactics
In February 2026, the FDA sent a letter to Novo Nordisk flagging a television advertisement for the newly launched Wegovy oral pill as containing “false or misleading” claims. The specific violations were revealing: the ad’s use of phrases like “live lighter” and “a way forward” were found to misleadingly imply that the pill delivered additional weight loss compared to other approved GLP-1 treatments — a claim not supported by clinical data. The FDA also took issue with the ad’s suggestion that the pill form offered “superior efficacy and/or safety” over injectable GLP-1 medications, which had not been demonstrated, and noted that the commercial misleadingly suggested emotional relief and reduced psychological burden beyond physical weight loss. The comparison between regulatory action and state lawsuits is instructive. When the FDA flags a misleading ad, the typical consequence is a request to pull or modify the commercial — a slap on the wrist, by most accounts.
Novo Nordisk confirmed receipt of the letter and said it was “in the process of responding to the FDA to address their concerns.” Compare that with the Texas lawsuits, which seek substantial financial penalties and could result in court-ordered changes to marketing practices. The tradeoff for patients is clear: FDA oversight is faster but has less bite, while state lawsuits are slower but carry the threat of real financial consequences. For anyone navigating the healthcare system on behalf of a loved one with dementia or cognitive impairment, the Wegovy case is a useful reminder to approach pharmaceutical advertising with healthy skepticism. Television ads are designed to sell, and even when they cross regulatory lines, the corrections often come months after millions of people have already been influenced. Caregivers should always discuss advertised medications with a physician who understands the patient’s full medical history before making any changes to a treatment plan.
Multistate Settlements and the Scope of Generic Drug Price-Fixing
The individual state lawsuits grab headlines, but the multistate settlements reveal the true scale of pharmaceutical industry misconduct. The $13.5 million settlement with Boehringer Ingelheim resolved allegations that the company engaged in off-label marketing and made deceptive claims about four prescription drugs: Micardis, Aggrenox, Atrovent, and Combivent. All 50 states and the District of Columbia participated, with Texas receiving $760,343 of the total. While $13.5 million may sound modest relative to the revenue these drugs generated, the settlement establishes a legal precedent and signals to other manufacturers that every state is watching. More alarming is the generic drug price-fixing landscape. A coalition of 48 states and territories secured $17.85 million from Lannett Company and Bausch Health over allegations that both companies engaged in widespread conspiracies to artificially inflate prices, reduce competition, and restrain trade for numerous generic prescription drugs.
But the story does not end there. A coalition of 42 states simultaneously filed a new lawsuit against Novartis and its subsidiary Sandoz, alleging a systemic campaign to fix prices, allocate markets, and rig bids for 31 different generic drugs. For patients on fixed incomes — a description that fits many older adults managing chronic conditions related to cognitive decline — price manipulation of generics is not an abstract legal matter. It directly determines whether they can afford their medications. The limitation to keep in mind with these settlements is that the dollar amounts, while symbolic, rarely compensate individual patients in any meaningful way. The $17.85 million split across 48 states translates to modest sums per jurisdiction, and the funds typically go into state general funds or consumer protection budgets rather than directly to affected patients. The real value of these cases lies in deterrence and in the discovery process, which often reveals internal documents showing what companies knew and when they knew it.
How These Cases Affect Patients Managing Dementia and Brain Health
Several of the drugs at the center of these lawsuits have direct relevance to dementia care and prevention. Plavix is prescribed to prevent strokes, which are a leading cause of vascular dementia. Aggrenox, one of the Boehringer Ingelheim settlement drugs, serves a similar purpose. If these medications were marketed deceptively — whether by hiding data about reduced effectiveness in certain populations or by making unsupported claims about their benefits — patients who relied on them may have been left inadequately protected against the very strokes that accelerate cognitive decline.
The Tylenol case raises a different but equally important concern for the brain health community. While the current lawsuit focuses on prenatal exposure and autism risk, the broader question of how pharmaceutical companies communicate neurological risks applies across the lifespan. Older adults with dementia are frequently prescribed medications for pain, sleep, and behavioral symptoms, and the information available to caregivers about potential cognitive side effects is only as reliable as the marketing and labeling those companies provide. When lawsuits reveal that companies withheld or downplayed neurological risks for years, it reinforces the need for caregivers to seek independent medical guidance rather than relying on manufacturer-provided information alone.
What Comes Next in the Fight Against Misleading Drug Marketing
The current wave of lawsuits and regulatory actions suggests that scrutiny of pharmaceutical marketing is intensifying, not winding down. Texas has positioned itself as the most aggressive state in this arena, but the multistate coalitions involving nearly every jurisdiction in the country indicate broad bipartisan support for holding drugmakers accountable. The new lawsuit against Novartis and Sandoz — filed by 42 states — signals that price-fixing in the generic drug market will face sustained legal pressure for years to come.
For patients and caregivers, the practical takeaway is to stay informed and maintain a critical eye toward pharmaceutical marketing of all kinds. The cases working through courts right now will take years to resolve, but their outcomes could fundamentally change what drug companies are allowed to say — and what they are required to disclose — about the medications millions of Americans take every day. In the meantime, the best defense against misleading marketing remains a trusted physician who knows the patient, independent research from sources like the FDA and peer-reviewed medical journals, and a willingness to ask hard questions about any medication that seems too good to be true.
Conclusion
The lawsuits against Bristol-Myers Squibb, Johnson & Johnson, Eli Lilly, Novo Nordisk, and others represent a significant legal reckoning for pharmaceutical marketing practices in the United States. From hiding data about a blood thinner’s reduced effectiveness in certain racial groups to allegedly bribing medical providers through free nurse programs, the allegations paint a picture of an industry where marketing priorities have at times overridden patient safety obligations. The multistate settlements with Boehringer Ingelheim and the generic drug price-fixing cases add further evidence that the problem is systemic rather than isolated.
For those caring for loved ones with dementia or managing their own brain health, these cases are a reminder that vigilance extends beyond the doctor’s office. The medications prescribed for stroke prevention, pain management, diabetes control, and other conditions that intersect with cognitive health are only as trustworthy as the information behind them. As these lawsuits advance, they have the potential to force greater transparency from drug manufacturers and give patients and caregivers the honest information they need to make truly informed medical decisions.
Frequently Asked Questions
Which states are leading lawsuits against drugmakers for misleading marketing?
Texas has been the most active state, with Attorney General Ken Paxton filing major lawsuits against Bristol-Myers Squibb and Sanofi over Plavix, Johnson & Johnson over Tylenol, and Eli Lilly over alleged kickback schemes. However, multistate coalitions involving all 50 states (in the Boehringer Ingelheim case) and 48 states (in the generic drug price-fixing cases) show that pharmaceutical accountability is a nationwide effort.
Is there a proven link between Tylenol and autism?
The link between prenatal acetaminophen exposure and autism remains scientifically contested. While some studies have suggested an association, a 2024 JAMA study found no causal link, and major health authorities have not confirmed a causal relationship. The Texas lawsuit against Johnson & Johnson and Kenvue alleges the companies should have disclosed the potential risk, but the science is not settled.
What was the Plavix lawsuit about?
Texas sued Bristol-Myers Squibb and Sanofi alleging that both companies knew since at least 1998 that Plavix had diminished or no effectiveness in Black, East Asian, and Pacific Islander patients due to genetic variations in drug metabolism. The FDA added a black box warning in 2010, but the lawsuit claims the companies failed to warn consumers and physicians for over a decade while generating billions in revenue.
How does the Eli Lilly kickback case affect prescribing?
Texas alleges Eli Lilly used a “Free Nurse Program” to provide free patient-care services to medical providers as a quid pro quo for prescribing drugs including Mounjaro and Zepbound. If true, this means some prescribing decisions were influenced by financial incentives rather than purely clinical judgment, potentially affecting patients who depend on their doctors for unbiased medication recommendations.
What happened with the Wegovy ad and the FDA?
In February 2026, the FDA sent Novo Nordisk a letter stating that a television ad for the new Wegovy oral pill contained false or misleading claims, including suggestions that the pill offered superior weight loss or safety compared to other GLP-1 treatments, which had not been demonstrated in clinical trials. The FDA requested immediate corrective action.
Do patients receive money from these pharmaceutical settlements?
In most multistate settlements, the funds go to state general funds or consumer protection budgets rather than directly to individual patients. For example, the $13.5 million Boehringer Ingelheim settlement was divided among all 50 states, with Texas receiving approximately $760,343. The primary benefit to patients comes through deterrence and increased transparency rather than direct financial compensation.
